Market Access Matters

In this episode, we hear from Megan O'Brien, Associate Director at Access Infinity, to explore why understanding payer perception is so difficult to capture in a structured way.  Megan shares how traditional KPIs like time to access and price only tell part of the story, and why the softer, more subjective elements of payer engagement, from communication frequency to corporate trust, can infl...

Most Favored Nation (MFN) pricing has taken over conversations at conferences, client meetings, and boardrooms alike, but what does it actually mean in practice? In this episode, we continue the conversation on evolving US pricing policy. Host Louise Bennett is joined by three of the Access Infinity team: Leigh Ann Bruhn, Louisa Byrne, and Richard Mee. Together, they discuss the current MFN landsc...

In this episode we sit down with Nikhil Taxak, Head of Pricing and Market Access Data Analytics at Access Infinity, to explore the rapidly evolving market access landscape. From the US Most Favored Nation (MFN) policy and Germany's Medical Research Act to surprising developments in Japan's pricing thresholds, Nikhil breaks down how these changes are reshaping pricing and reimbursement st...

In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated go...

In this episode, we invite Access Infinity Partner, Isabel Rubio back to the podcast  to explore the unique challenges and innovative solutions reshaping market access and pricing within rare disease.   Isabel shares insights from her extensive experience with due diligence assessments in orphan drug development, discussing three transformative strategies that are revolutionising how companies pro...

In this insightful episode we speak with Lizzie Shanahan, Global Access AI Strategy Lead at Sanofi. With over six years' experience at Sanofi and a rich background in commercial roles, Lizzie shares her unique journey into the world of market access and how her diverse experience shapes her approach to launch excellence. The conversation explores exciting developments in the industry, includi...

In this episode, we speak with Silvy Mardiguian, Senior Director and Head of HEOR for Europe & New Markets at BeiGene.   Silvy has been co-leading BeiGene’s preparedness and organisational readiness for the new Joint Clinical Assessment (JCA) framework, which is going to significantly change the EU HTA landscape. Silvy shares key insights into some of the learnings and challenges she has encou...

In this episode we chat with Jie Shen, who is Vice President Global Head Market Access at CSL.  Having started her career in pharma before the market access function existed, Jie is an industry veteran. We cover the changes she's seen over the last 24 years, including multi-stakeholder capitalisation - what it means to Jie and why she feels it's important for market access leaders. The o...

We're kicking off 2025 with a fantastic podcast episode featuring Katrin Jack, Global Access Strategy Head at Galderma and President of the Healthcare Businesswomen's Association Zürich-Zug Chapter.  This episode covers a lot of ground, from the 'sliding doors' moment that led Katrin into market access, to why she feels it's important for leaders to understand their core v...

In this episode we speak with Ezgi Erdogan who is Oncology Market Access Director for Emerging Markets at GSK.  In this discussion, we cover the unpredictability of emerging markets and the unique challenges this presents. Ezgi also shares her future predictions for access in emerging markets and talks about the importance of cross-functional collaboration in pharma to support the ever-changing la...

In this episode, we sit down with Pauline Payen, Director and Global Payer Strategy Lead for UCB’s Early Portfolio. Pauline shares her pragmatic insights into navigating the complexities of global market access.  Throughout her career, Pauline hasn't been shy of new opportunities, which has led to her taking on roles in commercial and marketing to expand her experience. In this discussion, we...

In this episode we're joined by GSK's Head of Market Access for General Medicines, Rupert Gale.  Rupert has been in pharma for over 27 years and is still going strong! In this discussion, he shares what resilience means to him and why he feels it's an important skill for market access leaders to leverage. Rupert shares some wonderful stories and advice that many of us can relate to...

Korinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development.  Korinna shares what led her into market access and explains what drives her to think outside the box to build and demonstrate a product's current and future value.   The opinions shared in this episode are Korinna’s own views and not represe...

In this episode we're joined by our first guest from Biotech - Ning Lu, who is Associate Director, International Pricing & Market Access at Blueprint Medicines. Ning shares her views on the complexities of market access and what makes the Biotech industry unique. She shares what inspired her to pursue a career in market access in biotechnology and why she feels it's a dynamic role an...

There’s no doubt that Market Access and Pricing leaders are fast becoming strategic partners in helping their wider organisations to understand the critical role of the function. In this episode, Marco Rauland from Merck KGaA joins us to explore this topic. Marco is Vice President Global Market Access and Pricing strategy, Pricing and Analytics. With over 25 years' experience in the field, he...

In this episode we're joined by Yvonne Hilsky who is Director of Market Access at Moderna. Having spent over 30 years in industry, Yvonne shares her views on what it takes to be successful in market access, including why making mistakes are an opportunity for growth.    Yvonne explores why it's important to have strong foundations and understand the 'building blocks' of market...

In this special episode which coincides with Disability Pride Month, we're joined by Senior Analyst Shubham Jadhav. Shubham has Becker Muscular Dystrophy (BMD) which is a form of muscular dystrophy and causes progressive muscle weakness.   Shubham is very passionate about raising awareness of rare diseases, disability, inclusivity and accessibility. He joins Keshav Nagaraja to share his story...

Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing.  Useful resources referenced in this podcast:  March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure...

In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Access functions, Joao shares his journey and how his strong HEOR background informs his current role.  Joao also explores the key pressures and challenges market access teams are facing and his views on the trends shaping the future...

In this episode we look at market access through a different lens. We're joined by Becky Germino who has extensive experience in HEOR across a broad range of pharma organisations.  Becky joined Sanofi this year as HEVA, Neurology and Immunology Team Leader and explains the key priorities for HEOR teams and their role in working closely with market access  to help them define and communicate p...

Adrian Harrington, Senior Director Value and Access at Biogen, joins the podcast to discuss market access excellence – what it means to him, and the critical role visual communication is playing for market access leaders. Adrian also shares his views on what’s next for the market access function, detailing why leaders must embrace opportunities to demonstrate the value of market access and tell th...

In this special episode, Louise teams up with colleagues Thomas Gilboy and Shravani Madishetti from Access Infinity to explore the transformative impact of digital on market access. Shravani, APAC Pricing and Market Access Lead, highlights the efficiency and accuracy achieved through digital tools while Tom, Product Owner for Nuro, emphasises the importance of maximising the effectiveness of digit...

In the third episode of series 2, Louise interviews Khalid Mirza, Senior Director, Global Market Access & Pricing, Oncology at Daiichi Sankyo.  They discuss Khalid's journey into market access, and how, for him, it's evolved into an exciting career path where science meets commercial. They also touch on the key themes shaping the future of market access, where Khalid's positive...

In this episode Louise teams up with Access Infinity Partner, Nick Proctor. Nick has been a consultant in the biopharmaceutical industry for over twenty years and shares his views on the hot topics and trends which he feels will have the biggest impact on market access in the coming years, also offering his insights on the themes which are 'hype'.  Throughout his career Nick has also bee...

Welcome back to the Market Access Matters podcast! In the first episode of series 2, Louise interviews David McConkey, Virology and Oncology Global Value and Access Director at Gilead Services.  Having started his career in consulting and then working across global and country roles, David has a breadth of experience in market access.  In this discussion he shares his experiences of taking on new...